felin
infecti
periton
fip
highli
fatal
diseas
caus
virul
felin
coronaviru
domest
wild
cat
previous
report
synthesi
potent
coronaviru
proteas
inhibitor
efficaci
proteas
inhibitor
clientown
cat
fip
studi
studi
effect
amino
acid
chang
felin
coronaviru
felin
patient
receiv
antivir
treatment
prolong
durat
gener
recombin
contain
identifi
amino
acid
chang
n
determin
suscept
proteas
inhibitor
fluoresc
reson
energi
transfer
assay
assay
show
confer
small
chang
increas
inhibitori
concentr
suscept
amino
acid
chang
affect
suscept
model
carri
amino
acid
chang
conduct
probe
structur
basi
find
result
studi
may
explain
observ
absenc
clinic
resist
longterm
antivir
treatment
patient
coronavirus
group
divers
rna
virus
caus
number
diseas
anim
human
coronavirus
singlestrand
positivesens
rna
genom
belong
famili
coronavirida
classifi
four
genera
alpha
beta
gamma
deltacoronavirus
king
et
al
felin
coronavirus
belong
genu
alphacoronaviru
caus
agent
enter
cat
felin
enter
coronaviru
infect
quit
common
multicat
environ
shelter
rescu
catteri
sinc
third
affect
cat
chronic
shed
virus
stool
felin
coronavirus
rel
stabl
environ
difficult
elimin
felin
coronavirus
affect
cat
popul
addi
et
al
pedersen
et
al
cat
infect
felin
coronavirus
may
show
mild
sever
enter
usual
recov
without
complic
howev
small
number
cat
may
develop
felin
infecti
periton
fip
highli
fatal
system
diseas
follow
enter
coronaviru
infect
pedersen
pedersen
detail
mechan
fip
develop
still
elus
believ
fip
aris
individu
cat
alter
viral
tropism
allow
viral
replic
macrophag
barker
et
al
chang
et
al
licitra
et
al
pedersen
et
al
pedersen
et
al
presenc
inadequ
cellular
immun
affect
cat
pedersen
fip
commonli
describ
wet
dri
form
base
presenc
absenc
effus
respect
form
may
switch
diseas
progress
cat
clinic
sign
fip
variabl
depend
affect
organ
may
includ
fever
jaundic
effus
weight
loss
neurolog
sign
ocular
lesion
pedersen
although
fip
almost
invari
fatal
cat
develop
clinic
sign
commerci
avail
treatment
licens
fip
support
treatment
avail
follow
viral
entri
host
cell
coronavirus
produc
viral
polyprotein
compos
nonstructur
viral
protein
subsequ
cleav
matur
function
viral
protein
virallyencod
proteas
papainlik
proteas
http
receiv
juli
receiv
revis
form
august
accept
august
releas
viral
protein
form
replicasetranscriptas
complex
requir
rna
replic
transcript
subgenom
rna
thu
inhibit
viral
proteas
block
viral
replic
previous
report
synthesi
proteas
inhibitor
felin
coronaviru
kim
et
al
kim
et
al
kim
et
al
show
efficaci
one
inhibitor
cat
experiment
induc
fip
kim
et
al
naturallyoccur
fip
field
trial
pedersen
et
al
also
report
amino
acid
chang
n
felin
coronaviru
collect
patient
treat
show
clinic
resist
multipl
round
treatment
field
trial
pedersen
et
al
studi
assess
effect
amino
acid
chang
felin
coronaviru
floresc
reson
energi
transfer
fret
assay
gener
carri
amino
acid
chang
also
conduct
model
carri
amino
acid
chang
compar
wildtyp
pretreat
probe
structur
basi
find
result
show
n
confer
statist
signific
small
reduct
suscept
increas
inhibitori
concentr
ic
compar
wildtyp
interestingli
none
amino
acid
chang
decreas
suscept
anoth
inhibitor
share
similar
structur
result
studi
may
explain
observ
absenc
clinic
resist
longterm
antivir
treatment
patient
field
trial
one
yearold
castrat
male
himalayan
cat
present
wet
form
fip
treat
field
trial
pedersen
et
al
diagnos
fip
base
physic
examin
signal
clinic
histori
laboratori
test
result
blood
effus
prior
enrol
trial
pedersen
et
al
admiss
exhibit
lethargi
inappet
abdomin
effus
enlarg
colon
lymph
node
treat
antibiot
prednisolon
prior
entri
trial
first
round
treatment
mgkg
inject
twice
daili
last
week
one
month
discontinu
treatment
relaps
fever
lethargi
retreat
mgkginject
twice
daili
week
treatment
remain
clinic
remiss
howev
week
follow
discontinu
second
treatment
relaps
typic
intraabdomin
lesion
without
neurolog
sign
euthan
pedersen
et
al
time
first
day
treatment
euthanasia
day
necropsi
tissu
sampl
collect
prepar
sequenc
analysi
felin
coronaviru
pedersen
et
al
comparison
amino
acid
sequenc
felin
coronaviru
pretreat
ascit
sampl
postmortem
tissu
sampl
previous
reveal
amino
acid
chang
n
kidney
n
lung
spleen
pedersen
et
al
fig
synthesi
inhibitor
previous
report
group
kim
et
al
fulllength
sequenc
felin
coronaviru
pretreat
ascit
sampl
design
wild
type
wt
amplifi
rtpcr
clone
vector
genscript
piscataway
nj
construct
recombin
contain
identifi
amino
acid
chang
singl
doubl
tripl
mutat
introduc
wt
gene
use
quickchang
ii
sitedirect
mutagenesi
kit
agil
technolog
santa
clara
ca
follow
manufactur
instruct
wt
mutant
clone
verifi
sequenc
analysi
clone
transform
cell
invitrogen
carlsbad
ca
express
protein
express
induc
luria
bertani
broth
mm
isopropyl
h
purifi
use
ninta
affin
column
qiagen
valencia
ca
store
activ
express
wt
mutant
determin
fret
assay
describ
previous
kim
et
al
assay
buffer
mix
assay
buffer
contain
fluorogen
substrat
dabacylktsavlqsgfrkmeedan
imag
micropl
assay
buffer
consist
mm
nacl
mm
dtt
mm
hepe
glycerol
ph
follow
incub
plate
min
fluoresc
measur
fluoresc
micropl
reader
biotek
winnooski
vt
background
substrat
subtract
fluoresc
read
read
compar
among
use
oneway
analysi
varianc
anova
tukey
post
hoc
test
graphpad
prism
version
graphpad
softwar
la
jolla
ca
confirm
activ
recombin
inhibit
assay
use
conduct
previous
describ
kim
et
al
kim
et
al
serial
dilut
assay
buffer
incub
assay
buffer
contain
min
mixtur
ad
assay
buffer
contain
fluorogen
substrat
well
plate
plate
incub
min
fluoresc
read
measur
floresc
micropl
reader
rel
fluoresc
calcul
subtract
background
fluoresc
fluoresc
read
ic
compound
calcul
nonlinear
regress
analysi
fourparamet
variabl
slope
use
graphpad
prism
softwar
least
four
independ
experi
conduct
determin
ic
valu
twotail
student
ttest
use
statist
comparison
ic
valu
determin
whether
residu
posit
conserv
amino
acid
sequenc
strain
felin
coronavirus
genbank
use
multipl
sequenc
align
use
clustal
omega
http
wwwebiacuktoolsmsa
clustalo
mcwilliam
et
al
threedimension
structur
wt
mutant
built
easymodel
program
version
kuntal
et
al
kim
et
al
therefor
model
structur
superimpos
crystal
structur
tgev
felin
coronaviru
compar
purpos
kim
et
al
ring
web
server
piovesan
et
al
use
studi
interact
residu
posit
residu
felin
coronaviru
activ
recombin
wt
mutant
fret
assay
shown
fig
statist
signific
differ
activ
among
indic
amino
acid
chang
affect
function
compar
wt
fig
inhibitori
activ
determin
wt
mutant
found
singl
amino
acid
chang
n
led
statist
signific
increas
ic
valu
compar
wt
fig
b
howev
increas
ic
valu
margin
foldchang
ic
carri
doubl
mutat
n
tripl
mutat
n
also
significantli
increas
ic
valu
respect
compar
wt
howev
ic
valu
doubl
tripl
mutat
statist
differ
carri
singl
mutat
fig
b
find
indic
n
mutat
affect
suscept
tripeptidyl
compound
share
similar
backbon
structur
similarli
potent
activ
felin
coronaviru
fret
assay
cell
cultur
kim
et
al
howev
unlik
differ
ic
valu
wt
singl
doubl
tripl
mutat
b
crystal
structur
felin
coronaviru
pdb
number
modifi
show
n
analyz
use
pymol
molecular
graphic
system
version
schroding
llc
cambridg
delano
adjac
catalyt
site
locat
domain
iii
near
c
terminu
multipl
sequenc
analysi
felin
coronaviru
strain
whose
sequenc
avail
pubm
databas
show
invari
conserv
felin
coronaviru
strain
also
highli
conserv
one
strain
arg
r
posit
fig
multipl
sequenc
align
felin
coronaviru
also
reveal
residu
form
hydrogen
bond
interact
tgev
kim
et
al
conserv
felin
coronavirus
data
shown
superposit
homolog
structur
wt
crystal
structur
pdb
access
number
felin
coronaviru
pdb
access
number
show
residu
align
close
catalyt
site
fig
c
suggest
residu
like
form
hydrogen
bond
felin
coronaviru
addit
seem
form
interact
locat
close
fig
c
catalyt
residu
activ
site
explor
potenti
interact
neighbor
residu
use
crystal
structur
felin
coronaviru
pdb
ring
web
server
predict
form
hydrogen
bond
main
chain
catalyt
residu
hydrogen
bond
length
respect
fig
substitut
asn
ser
posit
may
disrupt
format
put
hydrogen
bond
retain
hydrogen
bond
fig
predict
form
hydrogen
bond
main
chain
hydrogen
bond
length
respect
fig
substitut
ala
ser
posit
seem
fig
comparison
amino
acid
sequenc
felin
coronaviru
pretreat
mo
macrophag
postmortem
tissu
sampl
lung
kidney
spleen
amino
acid
chang
postmortem
tissu
sampl
indic
asterisk
ctermin
residu
includ
align
fig
activ
recombin
wildtyp
mutant
fret
assay
mix
fluorogen
substrat
assay
buffer
imag
micropl
incub
min
fluoresc
measur
fluoresc
micropl
reader
bar
repres
mean
standard
error
mean
fluoresc
unit
least
four
independ
fret
assay
statist
differ
p
activ
recombin
wt
indic
wildtyp
pretreat
n
indic
carri
singl
mutat
n
n
indic
doubl
tripl
mutat
respect
affect
hydrogen
bond
format
fig
predict
form
hydrogen
bond
main
chain
hydrogen
bond
length
respect
fig
substitut
ly
asn
posit
seem
affect
hydrogen
bond
format
fig
drug
resist
increas
concern
antivir
therapi
prolong
drug
exposur
high
viral
mutat
rate
greatli
reduc
suscept
drug
compromis
clinic
efficaci
antivir
treatment
emerg
drug
resist
influenc
multipl
factor
patient
complianc
immun
statu
patient
suboptim
dosag
drug
potenc
genet
barrier
drug
resist
viral
fit
biolog
viru
review
gott
strasfeld
chou
drug
resist
caus
develop
viral
mutat
aris
antivir
treatment
preexist
viru
variant
carri
mutat
viral
mutat
confer
variou
level
reduc
suscept
resist
drug
clinic
meaning
drug
resist
aris
viral
replic
insuffici
suppress
plasma
drug
concentr
antivir
compound
vari
genet
barrier
resist
low
genet
barrier
rel
readili
lead
emerg
mutat
associ
clinic
meaning
resist
may
suitabl
monotherapi
longer
durat
treatment
contrast
high
genet
barrier
reduc
risk
develop
resist
antivir
treatment
review
gott
strasfeld
chou
therefor
identifi
understand
drug
resist
antivir
compound
help
effect
treatment
regim
devis
felin
coronavirus
divid
serotyp
ii
base
antigen
addi
et
al
benetka
et
al
kummrow
et
al
pedersen
wang
et
al
serotyp
felin
coronavirus
predomin
type
field
hardli
grow
cell
cultur
previou
studi
report
serial
passag
serotyp
ii
felin
coronaviru
presenc
cell
cultur
lead
emerg
resist
virus
passag
although
tripeptidyl
compound
share
similar
backbon
structur
readili
led
resist
virus
kim
et
al
field
trial
identifi
amino
acid
chang
felin
coronaviru
felin
patient
receiv
intermitt
treatment
durat
month
fig
pedersen
et
al
patient
show
evid
clinic
drug
resist
treatment
howev
set
studi
natur
amino
acid
chang
felin
coronaviru
patient
serotyp
strain
base
sequenc
analysi
region
span
spike
gene
examin
effect
amino
acid
chang
suscept
gener
recombin
carri
amino
acid
chang
determin
chang
suscept
fret
assay
fig
among
singl
n
doubl
n
tripl
n
amino
acid
chang
contain
led
statist
signific
reduct
suscept
reduct
margin
increas
ic
compar
wt
fig
interestingli
n
singl
mutat
chang
suscept
potenti
effect
fret
assay
fig
consid
fact
plasma
drug
concentr
effect
concentr
ec
cat
receiv
drug
kim
et
al
result
combin
previou
find
observ
difficulti
rais
drug
resist
virus
cell
cultur
may
help
explain
absenc
clinic
drug
resist
patient
receiv
treatment
extend
period
field
trial
tripeptidyl
compound
share
core
structur
addit
residu
correspond
posit
previou
report
serial
passag
serotyp
ii
felin
coronaviru
presenc
readili
led
emerg
virus
phenotyp
increas
ec
compar
wt
kim
et
al
virus
singl
mutat
mutat
away
catalyt
site
interestingli
virus
retain
suscept
cell
cultur
kim
et
al
studi
fret
assay
show
amino
acid
substitut
affect
suscept
fig
b
confirm
although
share
similar
chemic
structur
dispar
mechan
induc
mutat
felin
coronaviru
report
avail
coronaviru
inhibitor
resist
deng
et
al
deng
et
al
report
singl
mutat
g
doubl
mutat
respons
resist
murin
hepat
viru
mhv
coronaviru
inhibitor
cell
cultur
mhv
carri
singl
mutat
partial
resist
inhibitor
compar
wt
viru
doubl
mutat
increas
viral
resist
cell
although
mutat
aros
rapidli
cell
cultur
indic
specif
inhibitor
lowgenet
barrier
resist
mutat
virus
reduc
viral
fit
cell
highli
attenu
host
mice
studi
locat
away
activ
site
mhv
fig
effect
recombin
wildtyp
mutant
fret
assay
incub
serial
dilut
min
fluorogen
substrat
ad
mixtur
follow
incub
min
fluoresc
read
measur
fluoresc
micropl
reader
determin
valu
bar
repres
mean
standard
error
mean
least
three
independ
fret
assay
b
fold
increas
valu
mutant
wt
shown
tabl
wt
indic
wildtyp
pretreat
n
indic
carri
singl
mutat
n
n
indic
doubl
tripl
mutat
respect
asterisk
indic
statist
signific
differ
compar
wt
p
respect
specul
affect
inhibitor
bind
indirectli
directli
although
role
domain
iii
unclear
deng
et
al
felin
coronaviru
activ
site
model
studi
show
loss
side
chain
substitut
predict
partial
lose
hydrogen
bond
residu
activ
site
fig
b
partial
loss
bond
may
explain
margin
reduct
suscept
substitut
model
studi
also
predict
n
substitut
domain
iii
fig
chang
interact
neighbor
residu
may
explain
find
fret
assay
mutat
seem
affect
proteolyt
activ
emerg
viral
resist
antivir
treatment
especi
longterm
treatment
concern
amino
acid
chang
found
felin
coronaviru
prepar
use
pymol
program
catalyt
residu
shown
green
shown
red
amino
acid
found
posit
among
felin
coronaviru
strain
whose
amino
acid
sequenc
avail
pubm
databas
shown
red
box
b
activ
site
superimpos
crystal
structur
tgev
pdb
access
teal
felin
coronaviru
pdb
access
slate
c
activ
site
superimpos
crystal
structur
tgev
pdb
access
teal
homolog
model
wt
pink
red
shown
red
stick
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
obtain
cat
patient
receiv
multipl
round
antivir
treatment
show
clinic
resist
substitut
led
statist
signific
slight
reduct
suscept
fret
assay
ic
chang
suscept
observ
substitut
result
studi
consist
previou
find
show
high
genet
barrier
felin
coronaviru
select
resist
studi
includ
xray
crystallographi
mutant
gener
recombin
virus
carri
mutat
help
us
gain
better
understand
role
substitut
research
fund
nation
institut
health
grant
number
morri
anim
foundat
grant
number
funder
role
design
studi
collect
analys
interpret
data
write
manuscript
decis
publish
result
yk
ko
wcg
patent
claim
proteas
inhibitor
manuscript
effect
amino
acid
chang
put
hydrogen
bond
format
felin
coronaviru
activ
site
wild
type
predict
hydrogen
bond
shown
panel
c
e
b
substitut
predict
result
loss
hydrogen
bond
dash
line
form
c
f
c
n
e
f
substitut
predict
affect
hydrogen
bond
hydrogen
bond
c
e
neighbor
amino
acid
felin
coronaviru
shown
distanc
measur
